<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-23788" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Isoproterenol</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Szymanski</surname>
            <given-names>Michael W.</given-names>
          </name>
          <aff>Stony Brook University-Southampton Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Singh</surname>
            <given-names>Davinder P.</given-names>
          </name>
          <aff>Shrimann Superspecialty Hospital, Jalandhar, Punjab</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Michael Szymanski declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Davinder Singh declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>1</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-23788.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Isoproterenol is a beta-1 and beta-2 adrenergic receptor agonist indicated primarily for bradydysrhythmias. The administration and subsequent post-administration monitoring of this medication are complex and necessitate an interprofessional approach to its usage. This activity covers isoproterenol, including mechanism of action, pharmacology, adverse event profiles, eligible patient populations, contraindications, monitoring, and highlights the role of the interprofessional team in the management of isoproterenol therapy.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify indications for the use of isoproterenol.</p></list-item><list-item><p>Describe the mechanism of action of isoproterenol.</p></list-item><list-item><p>Review potential complications arising from the use of isoproterenol.</p></list-item><list-item><p>Summarize the importance of an interprofessional team approach to the use of isoproterenol.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23788&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23788">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-23788.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Isoproterenol (also known as isoprenaline) is a drug used to treat bradycardia&#x000a0;conditions. the drug has a structural resemblance to epinephrine. It first received approval for use in the United States in 1947.</p>
        <p>Both approved and off-label indications for isoproterenol are as follows:</p>
        <p>
<bold>Isoproterenol Approved Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Heart block not requiring pacing&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Cardiac arrest from heart block when pacemaker therapy is unavailable<xref ref-type="bibr" rid="article-23788.r1">[1]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Off-label Uses</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Bradycardia</p>
          </list-item>
          <list-item>
            <p>Bronchospasm during anesthesia&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Cardiogenic shock</p>
          </list-item>
          <list-item>
            <p>Hypovolemic shock (adjunctive treatment)&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Provocation of ventricular arrhythmias in&#x000a0;arrhythmogenic&#x000a0;right ventricular cardiomyopathy: used during electrophysiological studies to induce ventricular arrhythmias in patients with a history of arrhythmogenic right ventricular cardiomyopathy</p>
          </list-item>
          <list-item>
            <p>Provocation&#x000a0;of syncope during tilt table testing</p>
          </list-item>
          <list-item>
            <p>Torsades&#x000a0;de pointes</p>
          </list-item>
          <list-item>
            <p>Beta-blocker overdose&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Ventricular arrhythmias secondary to AV block&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Short QT syndrome&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Electrical storm in patients with&#x000a0;Brugada syndrome</p>
          </list-item>
          <list-item>
            <p>Bradycardia in a cardiac transplant patient<xref ref-type="bibr" rid="article-23788.r2">[2]</xref><xref ref-type="bibr" rid="article-23788.r3">[3]</xref><xref ref-type="bibr" rid="article-23788.r4">[4]</xref><xref ref-type="bibr" rid="article-23788.r5">[5]</xref><xref ref-type="bibr" rid="article-23788.r6">[6]</xref><xref ref-type="bibr" rid="article-23788.r7">[7]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23788.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>
<bold>Isoproterenol is a beta-1 and beta-2 adrenergic receptor agonist resulting in&#x000a0;the following:&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Increased heart rate&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Increased heart contractility&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Relaxation of bronchial, gastrointestinal, and uterine smooth muscle&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Peripheral vasodilation&#x000a0;</p>
          </list-item>
        </list>
        <p>Both beta-1 and beta-2 adrenergic receptors exert their effects through a G-alpha stimulatory second messenger system. G-protein coupled receptors are structurally composed of a seven-transmembrane-spanning&#x000a0;protein. The extracellular domain serves as the ligand-binding site. In the inactivated state, the intracellular domain links to a G-alpha stimulatory protein bound to a GDP molecule. Upon binding of&#x000a0;the ligand to the extracellular domain of a&#x000a0;beta-1 receptor,&#x000a0;the alpha subunit exchanges a GDP molecule for a GTP and becomes activated. The (now active) G-alpha protein dissociates from the intracellular domain and activates&#x000a0;adenylate cyclase. Activated adenylate cyclase subsequently converts&#x000a0;intracellular ATP to cAMP.&#x000a0;The principal second messenger in this pathway, cAMP, activates protein kinase A (PKA). Activated PKA phosphorylates L-type calcium channels in cardiac myocytes, resulting in increased intracellular calcium. PKA also causes an increase in calcium release from ryanodine receptors on the sarcoplasmic reticulum.</p>
        <p>Beta-1 adrenergic receptors are primarily concentrated in heart tissue.&#x000a0;The terminal effects of activation of beta-1&#x000a0;adrenergic receptors&#x000a0;are&#x000a0;an increase in intracellular calcium. In cardiac pacemaker cells, increased calcium causes an increase in the slope of phase 4 of&#x000a0;the cardiac pacemaker action&#x000a0;potential. By increasing the slope of phase 4, pacemaker cells reach the threshold more rapidly, resulting in the characteristic increased heart rate seen in patients on an isoproterenol infusion. In non-pacemaker cardiac myocytes, an increase in intracellular&#x000a0;calcium causes the increased&#x000a0;contractility characteristic of isoproterenol infusion.<xref ref-type="bibr" rid="article-23788.r8">[8]</xref></p>
        <p>
<bold>The result of beta-1 agonism on the heart can be summarized&#x000a0;as follows:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Positive inotropy (contractility)</p>
          </list-item>
          <list-item>
            <p>Positive lusitropy (relaxation)</p>
          </list-item>
          <list-item>
            <p>Positive chronotropy (heart rate)</p>
          </list-item>
          <list-item>
            <p>Positive dromotropy (conduction velocity)&#x000a0;</p>
          </list-item>
        </list>
        <p>Beta-2 adrenergic receptors function similarly to beta-1 receptors&#x02014;activation of the G-protein coupled receptor results in an increase in intracellular cAMP. The second messenger, cAMP,&#x000a0;then activates protein kinase A (PKA). PKA phosphorylates&#x000a0;myosin light chain kinase&#x000a0;(MLCK),&#x000a0;thus inactivating it. In smooth muscle cells, MLCK is responsible for the phosphorylation of&#x000a0;myosin, leading to myosin-actin cross-bridge formation&#x000a0;and muscle contraction. As stated, agonism of beta-2 receptors leads to inactivation of MLCK and subsequent relaxation of smooth muscle, bronchial dilation, peripheral vasodilation, and gastrointestinal and uterine smooth muscle relaxation.<xref ref-type="bibr" rid="article-23788.r9">[9]</xref></p>
        <p>
<bold>Other effects of isoproterenol:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Hepatic glycogenolysis (beta-2)</p>
          </list-item>
          <list-item>
            <p>Release of glucagon from the pancreas (beta-2)</p>
          </list-item>
          <list-item>
            <p>Activation of the renin-angiotensin-aldosterone system in the kidney (beta-1)<xref ref-type="bibr" rid="article-23788.r10">[10]</xref></p>
          </list-item>
        </list>
        <p>Isoproterenol is metabolized in the liver via the CYP450 enzyme system.</p>
      </sec>
      <sec id="article-23788.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Isoproterenol is administered intravenously via an infusion pump. Note that adult&#x000a0;intravenous infusion is expressed as mcg/minutes. In contrast, the pediatric infusion is&#x000a0;expressed in mcg/kg/minute.</p>
        <p>
<bold>Available Forms</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Brand and generic: 0.2 mg/mL (1 mL, 5mL)&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p>
<bold>Bradydysrhythmias, AV Nodal Block</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>2 to 10 mcg/minute titrated to desired effect<xref ref-type="bibr" rid="article-23788.r2">[2]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Adam-Stokes Attacks</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>2 to 20 mcg/minute IV; Start at 5 mcg/minute IV</p>
          </list-item>
        </list>
        <p>
<bold>Brugada Syndrome (off-label)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Bolus 1 to 2 mcg followed by 0.15 to 0.3 mcg/minute for 24 hours<xref ref-type="bibr" rid="article-23788.r7">[7]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Cardiogenic Shock (off-label)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>2 to 20 mcg/minute continuous infusion<xref ref-type="bibr" rid="article-23788.r3">[3]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Provocation&#x000a0;of Syncope During Tilt Table Testing (off-label)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>1 mcg/minute, initially, then increase based on the desired response; max dose of 5 mcg/minute</p>
          </list-item>
        </list>
        <p>
<bold>Provocation of Ventricular Arrhythmias in Arrhythmogenic Right Ventricular Cardiomyopathy (off-label)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>45 mcg/minute for 3 minutes, then evaluate rhythm<xref ref-type="bibr" rid="article-23788.r4">[4]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Refractory Torsades de Pointes (off-label)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>2 to 10 mcg/minute continuous infusion titrated to patient response<xref ref-type="bibr" rid="article-23788.r6">[6]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Pediatric Dosage</bold>
</p>
        <p>
<bold>Bradycardia, AV Nodal Block</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>0.05 to 0.5 mcg/kg/minute IV, adjusted to desired effect; the max dosage&#x000a0;is 2 mcg/kg/minute<xref ref-type="bibr" rid="article-23788.r2">[2]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Neonatal Dosage</bold>
</p>
        <p>
<bold>Bradycardia</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>0.05 to 1 mcg/kg/minute continuous infusion titrated to effect<xref ref-type="bibr" rid="article-23788.r11">[11]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p>Isoproterenol is immediately active upon infusion. Its half-life is 2.5 to 5 minutes. Conjugation in hepatic and pulmonary tissues is the major method of metabolism. Excretion occurs via urine in the form of sulfate conjugates.&#x000a0;</p>
        <p>
<bold>Pregnancy/Breastfeeding</bold>
</p>
        <p>The use of isoproterenol during pregnancy has not been evaluated. The presence of isoproterenol in breast milk is presently&#x000a0;unknown.<xref ref-type="bibr" rid="article-23788.r12">[12]</xref></p>
        <p>
<bold>Renal and Hepatic Dosing</bold>
</p>
        <p>Renal and hepatic dosing is undefined.</p>
      </sec>
      <sec id="article-23788.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>
<bold>Common</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Headache</p>
          </list-item>
          <list-item>
            <p>Dizziness</p>
          </list-item>
          <list-item>
            <p>Upset stomach</p>
          </list-item>
          <list-item>
            <p>Flushing</p>
          </list-item>
          <list-item>
            <p>Fatigue</p>
          </list-item>
          <list-item>
            <p>Nervousness</p>
          </list-item>
          <list-item>
            <p>Diaphoresis</p>
          </list-item>
          <list-item>
            <p>Blurred vision</p>
          </list-item>
          <list-item>
            <p>Tachyarrhythmia</p>
          </list-item>
          <list-item>
            <p>Hypertension/hypotension</p>
          </list-item>
        </list>
        <p><bold>Cardiovascular</bold>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Angina&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Flushing&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Hypotension&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Hypertension&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Palpitations&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Ventricular arrhythmia&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Premature ventricular contractions&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Adams-stokes syndrome&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Bradycardia (with tilt table testing)&#x000a0;</p>
          </list-item>
        </list>
        <p><bold>Respiratory</bold>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Dyspnea&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Edema&#x000a0;</p>
          </list-item>
        </list>
        <p><bold>Ophthalmic</bold>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Blurred vision&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Central Nervous System</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Headache</p>
          </list-item>
          <list-item>
            <p>Dizziness</p>
          </list-item>
          <list-item>
            <p>Nervousness</p>
          </list-item>
          <list-item>
            <p>Restlessness</p>
          </list-item>
          <list-item>
            <p>Seizures&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Gastrointestinal</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Nausea</p>
          </list-item>
          <list-item>
            <p>Vomiting&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Endocrine &#x00026; Metabolic</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Hypokalemia</p>
          </list-item>
          <list-item>
            <p>Increased serum glucose&#x000a0;</p>
          </list-item>
        </list>
        <p><bold>Musculoskeletal</bold>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>&#x000a0;Tremor</p>
          </list-item>
          <list-item>
            <p>Weakness&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23788.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>
<bold>Absolute Contraindications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Angina</p>
          </list-item>
          <list-item>
            <p>Tachydysrhythmias</p>
          </list-item>
          <list-item>
            <p>Preexisting ventricular arrhythmias</p>
          </list-item>
          <list-item>
            <p>Digoxin intoxication</p>
          </list-item>
          <list-item>
            <p>Sulfa allergy: Contains sulfites</p>
          </list-item>
        </list>
        <p>Isoproterenol requires caution in patients with&#x000a0;the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Cardiovascular disease: Isoproterenol causes an increase in myocardial oxygen demand</p>
          </list-item>
          <list-item>
            <p>Diabetes: May cause an increase in blood glucose levels</p>
          </list-item>
          <list-item>
            <p>Distributive shock: Beta-2 agonism will further decrease total peripheral resistance</p>
          </list-item>
          <list-item>
            <p>Hyperthyroidism: May induce thyroid storm</p>
          </list-item>
          <list-item>
            <p>The drug contains sulfites which may provoke an allergic reaction in patients with a sulfa allergy</p>
          </list-item>
          <list-item>
            <p>Elderly</p>
          </list-item>
        </list>
        <p>
<bold>Pregnancy </bold>
</p>
        <p>Isoproterenol is a Pregnancy Risk Factor C. It may interfere with uterine contractions due to its beta-2 agonist properties. Animal reproduction studies have not been conducted&#x000a0;at this time. It is currently&#x000a0;unknown if isoproterenol is present in breast milk; breastfeeding mothers are advised to exercise caution when taking isoproterenol. There is no human data available regarding the effect of isoproterenol on milk production.<xref ref-type="bibr" rid="article-23788.r12">[12]</xref>&#x000a0;</p>
        <p>
<bold>Drug Interactions</bold>
</p>
        <p>
<bold>Risk C: Monitor Therapy</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Atomoxetine: Propensity to increase heart rate</p>
          </list-item>
          <list-item>
            <p>Cannabinoid-containing products: Propensity to increase heart rate</p>
          </list-item>
          <list-item>
            <p>COMT Inhibitors: Isoproterenol is degraded by catechol O-methyltransferase (COMT) and may rise to dangerous levels in the presence of a COMT inhibitor</p>
          </list-item>
          <list-item>
            <p>Doxofylline: Increased risk of doxofylline toxicity</p>
          </list-item>
          <list-item>
            <p>Tedizolid: Increased risk of a hypertensive episode</p>
          </list-item>
        </list>
        <p>
<bold>Risk D: Consider Modifying Therapy</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Topical Cocaine: Heightened risk of hypertension, tachycardia, and increased oxygen demand</p>
          </list-item>
          <list-item>
            <p>Linezolid: Increased risk of hypertension due to COMT inhibitor-like action of linezolid</p>
          </list-item>
          <list-item>
            <p>Mifepristone: QTc prolongation</p>
          </list-item>
          <list-item>
            <p>QTc prolonging agents: Avoid giving isoproterenol in combination with other QTc prolonging agents.</p>
          </list-item>
        </list>
        <p>
<bold>Risk X: Avoid or Use Alternatives</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Inhaled Anesthetics: Increased risk of arrhythmia</p>
          </list-item>
          <list-item>
            <p>Benzphetamine</p>
          </list-item>
          <list-item>
            <p>Clomipramine</p>
          </list-item>
          <list-item>
            <p>Diethylpropion</p>
          </list-item>
          <list-item>
            <p>Epinephrine</p>
          </list-item>
          <list-item>
            <p>Methamphetamine</p>
          </list-item>
          <list-item>
            <p>Midodrine</p>
          </list-item>
          <list-item>
            <p>Phendimetrazine</p>
          </list-item>
          <list-item>
            <p>Procarbazine</p>
          </list-item>
          <list-item>
            <p>Sotalol</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23788.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Clinicians should record electrolytes, blood pressure, and ECG at baseline. Vitals (i.e., heart rate, respiratory rate, blood pressure), in addition to ECG, arterial blood gas, blood glucose levels, and serum potassium and magnesium levels, require continuous monitoring in patients receiving isoproterenol.</p>
      </sec>
      <sec id="article-23788.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Acute toxicity&#x000a0;from isoproterenol can cause a&#x000a0;significant drop in blood pressure.&#x000a0;In instances of accidental overdosage, as evidenced mainly by tachycardia or other arrhythmias, hypotension/hypertension, or angina, either reduce the rate of isoproterenol administration or discontinue the drug until the patient has stabilized. Pulse, respiration, ECG, and blood pressure should all be monitored regularly. There is no known reversal agent for humans, although studies are underway to look for agents to address toxicity.<xref ref-type="bibr" rid="article-23788.r13">[13]</xref></p>
      </sec>
      <sec id="article-23788.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>A cardiologist most often prescribes isoproterenol. However, the use&#x000a0;of the drug requires an interprofessional&#x000a0;team that consists of ICU nurses and other nursing staff, intensivists, cardiologists, cardiac surgeons, critical care specialists, and pharmacists. The drug only has an application as an intravenous drip for severe bradycardia and cardiac arrest. It is sometimes used to manage hypovolemic shock and bronchospasm. Isoproterenol can cause tachyarrhythmias and hypertension at high doses. When used in the ICU, the patient requires close monitoring. Because of the availability of pacemakers and other chronotropic drugs, the use of isoproterenol has diminished in the current medical paradigm.<xref ref-type="bibr" rid="article-23788.r14">[14]</xref></p>
        <p>As stated, isoproterenol requires interprofessional collaboration for effective use. The ordering clinician (MD, DO, NP, or PA) decides to use the drug, but the entire healthcare team&#x000a0;must be&#x000a0;involved. This team includes specialists, as listed above, as well as pharmacists and other nursing staff.</p>
        <p>The pharmacist needs to verify dosing and perform thorough medication reconciliation; it would be prudent to enlist the assistance of a Board Certified Cardiology pharmacist when ordering isoproterenol, as their extensive additional training can be a good resource for the team regarding interactions, dosing and dose adjustments, and advising the team on what to monitor for potential adverse events.</p>
        <p>Nursing is at the front lines for entering patient medication history and also conducting the monitoring necessary when administering isoproterenol. Any abnormal results or concerns require communication with the team,&#x000a0;including clinicians and the pharmacy, for dosing or drug changes. This is essential, given the nature of the conditions treated with isoproterenol and the potential adverse events and/or drug interactions, which can cause severe problems for the patient&#x02014;as with pharmacy, having nursing staff with additional specialized cardiology training can prove to be of significant benefit. Only with this type of collaborative team effort and interprofessional communication can the interprofessional team optimize isoproterenol therapy, resulting in improved outcomes with fewer adverse events. [Level 5]</p>
      </sec>
      <sec id="article-23788.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23788&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23788">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/23788/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=23788">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-23788.s11">
        <title>References</title>
        <ref id="article-23788.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Field</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Hazinski</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Sayre</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Chameides</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Schexnayder</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Hemphill</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Samson</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Kattwinkel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Berg</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Bhanji</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cave</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Jauch</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Kudenchuk</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Neumar</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Peberdy</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Perlman</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Sinz</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Travers</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Berg</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Billi</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Eigel</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hickey</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Kleinman</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Link</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Morrison</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>O'Connor</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Shuster</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Callaway</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Cucchiara</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ferguson</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Rea</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Vanden Hoek</surname>
                <given-names>TL</given-names>
              </name>
            </person-group>
            <article-title>Part 1: executive summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care.</article-title>
            <source>Circulation</source>
            <year>2010</year>
            <month>Nov</month>
            <day>02</day>
            <volume>122</volume>
            <issue>18 Suppl 3</issue>
            <fpage>S640</fpage>
            <page-range>S640-56</page-range>
            <pub-id pub-id-type="pmid">20956217</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23788.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Neumar</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Otto</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Link</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Kronick</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Shuster</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Callaway</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Kudenchuk</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Ornato</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>McNally</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Silvers</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Passman</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Hess</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sinz</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Morrison</surname>
                <given-names>LJ</given-names>
              </name>
            </person-group>
            <article-title>Part 8: adult advanced cardiovascular life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care.</article-title>
            <source>Circulation</source>
            <year>2010</year>
            <month>Nov</month>
            <day>02</day>
            <volume>122</volume>
            <issue>18 Suppl 3</issue>
            <fpage>S729</fpage>
            <page-range>S729-67</page-range>
            <pub-id pub-id-type="pmid">20956224</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23788.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Diepen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Katz</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Albert</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Henry</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Jacobs</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Kapur</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Kilic</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Menon</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ohman</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Sweitzer</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Thiele</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Washam</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>MG</given-names>
              </name>
              <collab>American Heart Association Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; and Mission: Lifeline</collab>
            </person-group>
            <article-title>Contemporary Management of Cardiogenic Shock: A Scientific Statement From the American Heart Association.</article-title>
            <source>Circulation</source>
            <year>2017</year>
            <month>Oct</month>
            <day>17</day>
            <volume>136</volume>
            <issue>16</issue>
            <fpage>e232</fpage>
            <page-range>e232-e268</page-range>
            <pub-id pub-id-type="pmid">28923988</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23788.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Denis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sacher</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Derval</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Cochet</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Daly</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pillois</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Ramoul</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Komatsu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zemmoura</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Amraoui</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ritter</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ploux</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bordachar</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hocini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ja&#x000ef;s</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ha&#x000ef;ssaguerre</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Diagnostic value of isoproterenol testing in arrhythmogenic right ventricular cardiomyopathy.</article-title>
            <source>Circ Arrhythm Electrophysiol</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>7</volume>
            <issue>4</issue>
            <fpage>590</fpage>
            <page-range>590-7</page-range>
            <pub-id pub-id-type="pmid">24970294</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23788.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Benditt</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Ferguson</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Grubb</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Kapoor</surname>
                <given-names>WN</given-names>
              </name>
              <name>
                <surname>Kugler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lerman</surname>
                <given-names>BB</given-names>
              </name>
              <name>
                <surname>Maloney</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Raviele</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ross</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sutton</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wolk</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Wood</surname>
                <given-names>DL</given-names>
              </name>
            </person-group>
            <article-title>Tilt table testing for assessing syncope. American College of Cardiology.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>1996</year>
            <month>Jul</month>
            <volume>28</volume>
            <issue>1</issue>
            <fpage>263</fpage>
            <page-range>263-75</page-range>
            <pub-id pub-id-type="pmid">8752825</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23788.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al-Khatib</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Ackerman</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Bryant</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Callans</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Curtis</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Deal</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Dickfeld</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Field</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Fonarow</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Gillis</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Granger</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Hammill</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Hlatky</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Joglar</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Kay</surname>
                <given-names>GN</given-names>
              </name>
              <name>
                <surname>Matlock</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Myerburg</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Page</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.</article-title>
            <source>Circulation</source>
            <year>2018</year>
            <month>Sep</month>
            <day>25</day>
            <volume>138</volume>
            <issue>13</issue>
            <fpage>e272</fpage>
            <page-range>e272-e391</page-range>
            <pub-id pub-id-type="pmid">29084731</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23788.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Watanabe</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fukushima Kusano</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Morita</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Miura</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sumida</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Hiramatsu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Banba</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nishii</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Nagase</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nakamura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sakuragi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ohe</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Low-dose isoproterenol for repetitive ventricular arrhythmia in patients with Brugada syndrome.</article-title>
            <source>Eur Heart J</source>
            <year>2006</year>
            <month>Jul</month>
            <volume>27</volume>
            <issue>13</issue>
            <fpage>1579</fpage>
            <page-range>1579-83</page-range>
            <pub-id pub-id-type="pmid">16760208</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23788.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Desimine</surname>
                <given-names>VL</given-names>
              </name>
              <name>
                <surname>McCrink</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Parker</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Wertz</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Maning</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lymperopoulos</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Biased Agonism/Antagonism of Cardiovascular GPCRs for Heart Failure Therapy.</article-title>
            <source>Int Rev Cell Mol Biol</source>
            <year>2018</year>
            <volume>339</volume>
            <fpage>41</fpage>
            <page-range>41-61</page-range>
            <pub-id pub-id-type="pmid">29776604</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23788.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Matera</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Page</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rinaldi</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>&#x003b2;2-Adrenoceptor signalling bias in asthma and COPD and the potential impact on the comorbidities associated with these diseases.</article-title>
            <source>Curr Opin Pharmacol</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>40</volume>
            <fpage>142</fpage>
            <page-range>142-146</page-range>
            <pub-id pub-id-type="pmid">29763833</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23788.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Biazi</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Frasson</surname>
                <given-names>IG</given-names>
              </name>
              <name>
                <surname>Miksza</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>de Morais</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>de Fatima Silva</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bertolini</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>de Souza</surname>
                <given-names>HM</given-names>
              </name>
            </person-group>
            <article-title>Decreased hepatic response to glucagon, adrenergic agonists, and cAMP in glycogenolysis, gluconeogenesis, and glycolysis in tumor-bearing rats.</article-title>
            <source>J Cell Biochem</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>119</volume>
            <issue>9</issue>
            <fpage>7300</fpage>
            <page-range>7300-7309</page-range>
            <pub-id pub-id-type="pmid">29761924</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23788.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Matsubara</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Morimatsu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Shiraishi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kuwata</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ohkuchi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Izumi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Takeda</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Fetus with heart failure due to congenital atrioventricular block treated by maternally administered ritodrine.</article-title>
            <source>Arch Gynecol Obstet</source>
            <year>2008</year>
            <month>Jul</month>
            <volume>278</volume>
            <issue>1</issue>
            <fpage>85</fpage>
            <page-range>85-8</page-range>
            <pub-id pub-id-type="pmid">18066569</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23788.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mahon</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Reid</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Day</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>The in vivo effects of beta adrenergic stimulation and blockade on the human uterus at term.</article-title>
            <source>J Pharmacol Exp Ther</source>
            <year>1967</year>
            <month>Apr</month>
            <volume>156</volume>
            <issue>1</issue>
            <fpage>178</fpage>
            <page-range>178-85</page-range>
            <pub-id pub-id-type="pmid">6023594</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23788.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shackebaei</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hesari</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ramezani-Aliakbari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hoseinkhani</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Ramezani-Aliakbari</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Gallic acid protects against isoproterenol-induced cardiotoxicity in rats.</article-title>
            <source>Hum Exp Toxicol</source>
            <year>2022</year>
            <season>Jan-Dec</season>
            <volume>41</volume>
            <fpage>9603271211064532</fpage>
            <pub-id pub-id-type="pmid">35193428</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23788.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kislitsina</surname>
                <given-names>ON</given-names>
              </name>
              <name>
                <surname>Rich</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Wilcox</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Pham</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Churyla</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vorovich</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Ghafourian</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yancy</surname>
                <given-names>CW</given-names>
              </name>
            </person-group>
            <article-title>Shock - Classification and Pathophysiological Principles of Therapeutics.</article-title>
            <source>Curr Cardiol Rev</source>
            <year>2019</year>
            <volume>15</volume>
            <issue>2</issue>
            <fpage>102</fpage>
            <page-range>102-113</page-range>
            <pub-id pub-id-type="pmid">30543176</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
